MX1 and leukemia: Given the variation in leukemogenic potential among CBFβ-SMMHC and its related mutants, we performed RNA sequencing on LK cells isolated from control, Mx1-CreCbfb+/56M, Mx1-CreCbfb+/56M-ΔHABD, and Mx1-CreCbfb+/mDE mice (2–3 weeks after pIpC treatment) and then integrated gene expression profiles with the leukemogenic potential to identify genes and pathways responsible for CBFβ-SMMHC–induced leukemia development.